Brought to you by 
Genfit, UCB Pharma develop respiratory, allergy drugs
13 Sep 2001
Executive Summary
Genfit (drug discovery; focuses mostly on cardiovascular, metabolic, and inflammatory diseases, with some interest in CNS disorders) and UCB Pharma (immuno-allergy, central nervous system) will identify and validate target genes to develop drugs in allergy and respiratory diseases, including asthma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genfit, UCB Pharma develop respiratory, allergy drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice